Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

60.30 -0.70 (-1.15%)
Streaming Delayed Price Updated: 9:43 AM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Moderna Before Aug. 5? ↗
Moderna just received fantastic news. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Which S&P500 stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy? ↗
The company's pending vaccine approvals could help the stock continue its rise. 
Via The Motley Fool
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
From Moderna, Inc.
Via ACCESS Newswire
News headline image
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
They haven't peaked yet. 
Via The Motley Fool
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Moderna to Host Investor Event - Science Day
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Why Is Moderna (MRNA) Stock Soaring Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.1% in the afternoon session after investors positioned ahead of a pivotal FDA a... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Stocks Under $50 That Fall Short
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗
It's important to consider your comfort with risk before diving in. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
3 Unpopular Stocks We Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Does Moderna Need to Start Making Money? ↗
Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy. 
Via The Motley Fool
News headline image
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Via ACCESS Newswire
News headline image
3 ETFs For the Coming Genomics Revolution ↗
Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit. 
Via MarketBeat
Topics ETFs
News headline image
Why Is Moderna (MRNA) Stock Rocketing Higher Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as... 
Via StockStory
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.